A subscription to JoVE is required to view this content. Sign in or start your free trial.
The method presented here can evaluate the effect of reagents on angiogenesis or vascular permeability in vivo without staining. The method uses dextran-FITC injection via the tail vein to visualize neo-vessels or vascular leakage.
Several models have been developed to investigate angiogenesis in vivo. However, most of these models are complex and expensive, require specialized equipment, or are hard to perform for subsequent quantitative analysis. Here we present a modified matrix gel plug assay to evaluate angiogenesis in vivo. In this protocol, vascular cells were mixed with matrix gel in the presence or absence of pro-angiogenic or anti-angiogenic reagents, and then subcutaneously injected into the back of recipient mice. After 7 days, phosphate buffer saline containing dextran-FITC is injected via the tail vein and circulated in vessels for 30 min. Matrix gel plugs are collected and embedded with tissue embedding gel, then 12 µm sections are cut for fluorescence detection without staining. In this assay, dextran-FITC with high molecular weight (~150,000 Da) can be used to indicate functional vessels for detecting their length, while dextran-FITC with low molecular weight (~4,400 Da) can be used to indicate the permeability of neo-vessels. In conclusion, this protocol can provide a reliable and convenient method for the quantitative study of angiogenesis in vivo.
Angiogenesis, the process of formation of neo-vessels from pre-existing vessels, plays a critical role in many physiological and pathological processes, such as embryonic development, wound healing, atherosclerosis, tumor development, etc.1,2,3,4,5. This dynamic process involves several steps, including the degradation of the matrix, vascular cell proliferation, migration and self-organization to form tubular structures and the stabilization of the neo-vessels6. Promoting angiogenesis has been demonstrated to be critical in the treatment of myocardial infarction, stroke and other kinds of ischemic diseases7 while inhibiting angiogenesis has been considered a promising strategy in the treatment of cancers8 and rheumatoid diseases9. Angiogenesis has been considered an organizing principle for drug discovery10. Thus, the construction of a reliable and convenient method to assess the extent of angiogenesis is critical for mechanical research or drug discovery in angiogenesis-dependent diseases.
Several in vitro and in vivo models have been developed to evaluate angiogenesis11. Among these, two-dimensional (2-D) models, like matrix gel tube formation assay12, cannot form functional tubular structures. The animal models, such as the hind limb ischemia model13,14, can reproduce the angiogenesis process but are complex and require a laser speckle blood flow imaging system. 3D models of vascular morphogenesis, like matrix gel plug assay, provide a simple platform that can mimic the process of angiogenesis in vivo15, but the detection of angiogenesis requires immunohistochemistry or immunofluorescence staining16,17,18, which are variable and poorly visualized.
Here, we describe a protocol for a modified matrix gel plug assay where vascular cells were mixed with matrix gel and subcutaneously injected into the back of mice to form a plug. In the plug, vascular cells need to degrade the matrix, proliferate, migrate, and self-organize to finally form functional vessels with blood flow in the internal environment. Thereafter, fluorescent-labeled dextran is injected via the tail vein, to flow through the plug, and the label is visualized to indicate neo-vessels. The content of angiogenesis can be quantitatively evaluated by the length of the vessels. This method can form functional vessels that cannot be produced in 2-D angiogenesis models12, and does not need complex stain process as in ordinary matrix gel plug assay11. It also does not require expensive specific instruments like laser speckle blood flow imaging system in hind limb ischemia model13,14,19. This method is versatile, low-cost, quantifiable, and easy to perform, and can be used to determine the pro- or anti-angiogenic capability of drugs or be used in mechanical research involved in angiogenesis.
All procedures involving animal subjects were approved by the Institutional Animal Care and Use Committee (IACUC) of Wenzhou Medical University (XMSQ2021-0057, July 19th, 2021). All reagents and consumables are listed in the Table of Materials.
1. Culture medium preparation
2. Vascular cell preparation
3. Matrix gel preparation
4. Mouse preparation
5. Matrix gel mixture injection
6. Dextran-FITC injection through the tail vein
7. Matrix gel plug collection
8. Embedding matrix gel plug and section preparation
9. Quantification of angiogenesis (Figure 3)
10. Quantification of vascular permeability (Figure 4)
Figure 1 is the flowchart depicting how to prepare the mixture of matrix gel, vascular cells, culture medium and reagent. The mixture was then subcutaneously injected into the back of Nu/Nu mice and heated using a heating pad to accelerate its coagulation to finally form gel plug.
Figure 2A is the flowchart to indicate vessels with fluorescent labeled dextran. Fluorescent labeled dextran was injected via the tail vein and circle for 3...
We present a reliable and convenient method for the quantitative evaluation of angiogenesis in vivo without staining. In this protocol, vascular cells were mixed with matrix gel in the presence of pro-angiogenic or anti-angiogenic reagents, and then subcutaneously injected into the back of Nu/Nu mice to form gel plug (Figure 1). After 7 days of gel plug formation, dextran-FITC was intravenously injected and circulated for 30 min. The gel plug was collected and embedded with tissue e...
The authors declare no conflict of interest.
This work was funded by Natural Science Foundation of Zhejiang Province (LY22H020005), and National Natural Science Foundation of China (81873466).
Name | Company | Catalog Number | Comments |
Adhesion Microscope Slides | CITOTEST | 188105 | |
Anesthesia System | RWD | R640-S1 | |
Cell Counter | Invitrogen | AMQAX1000 | |
Cell Culture Dish | Corning | 430167 | |
Cryoslicer | Thermo Fisher | CryoStar NX50 | |
Dextrans-FITC-150kDa | WEIHUA BIO | WH007N07 | |
Dextrans-FITC-4kDa | WEIHUA BIO | WH007N0705 | |
Embedding Cassettes | CITOTEST | 80203-0007 | |
Endothelial Cell Medium | ScienCell | 35809 | |
Endothelial Growth Supplements | ScienCell | 1025 | |
Fetal Bovine Serum | Gibco | 10100147C | |
Fibroblast Growth Factor 1 | AtaGenix | 9043p-082318-A01 | FGF1 |
Fluorescence Microscope | Nikon | ECLIPSE Ni | |
Heating Pad | Boruida | 30-50-30 | |
Insulin Syringe | BD | 300841 | |
Isoflurane | RWD | R510-22-10 | |
Laboratory Balance | Sartorius | BSA124S-CW | |
Matrigel | Corning | 356234 | Matrix gel |
Medium 199 powder | Gibco | 31100-035 | |
Microtubes | Axygen | MCT-150-C | |
Optimal Cutting Temperature (OCT) Compound | SUKURA | 4583 | Tissue embedding gel |
Palmitate Acid | KunChuang | KC001 | |
Penicillin-Streptomycin Liquid | Solarbio | P1400 | |
Phosphate Buffer Saline | Solarbio | P1022 | |
Surgical Instruments | RWD | RWD | |
Tail Vein Injection Instrument | KEW BASIS | KW-XXY | |
Trypsin-EDTA Solution | Solarbio | T1320 | |
Ultra-Low Temperature Freezer | eppendorf | U410 | |
Vascular Endothelial Growth Factor | CHAMOT | CM058-5HP | VEGF |
Request permission to reuse the text or figures of this JoVE article
Request PermissionThis article has been published
Video Coming Soon
Copyright © 2025 MyJoVE Corporation. All rights reserved